Price Chart

Profile

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
URL https://www.interceptpharma.com
Investor Relations URL https://ir.interceptpharma.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 01, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
URL https://www.interceptpharma.com
Investor Relations URL https://ir.interceptpharma.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 01, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A